By a News Reporter-Staff News Editor at Biotech Week -- Research findings on Oncology are discussed in a new report. According to news originating from Kansas City, Missouri, by NewsRx correspondents, research stated, "Over the past 50 years, numerous advances in treatment have produced dramatic increases in the cure rates of pediatric leukemias. Despite this progress, the majority of children with relapsed leukemia are not expected to survive."
Our news journalists obtained a quote from the research from Children's Mercy Hospitals and Clinics, "With current chemotherapy regimens, approximately 15 % of children with acute lymphoblastic leukemia and 45 % of children with acute myeloid leukemia will have refractory disease or experience a relapse. Advances in the treatment of pediatric relapsed leukemia have not mirrored the successes of upfront therapy, and newer treatments are desperately needed in order to improve survival in these challenging patients. Recent improvements in our knowledge of cancer biology have revealed an extensive number of targets that have the potential to be exploited for anticancer therapy. These advances have led to the development of a number of new treatments that are now being explored in children with relapsed or refractory leukemia. Novel agents seek to exploit the same molecular aberrations that contribute to leukemia development and resistance to therapy. Newer classes of drugs, including monoclonal antibodies, tyrosine kinase inhibitors and epigenetic modifiers are transforming the treatment of patients who are not cured with conventional therapies. As the side effects of many new agents are distinct from those seen with conventional chemotherapy, these treatments are often explored in combination with each other or combined with conventional treatment regimens."
According to the news editors, the research concluded: "This review discusses the biological rationale for the most promising new agents and the results of recent studies conducted in pediatric patients with relapsed leukemia."
For more information on this research see: Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions. Drugs, 2013;73(5):439-61. Drugs can be contacted at: Adis International LTD, 41 Centorian Dr, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand. (Emerald Group Publishing - www.emeraldinsight.com; Drugs - www.emeraldinsight.com/journals.htm?issn=1745-9265)
The news correspondents report that additional information may be obtained from K.J. August, Children's Mercy Hospitals and Clinics, 2401 Gillham Road, Kansas City, MO, United States. Additional authors for this research include A. Narendran and K.A Neville (see also Oncology).
The publisher's contact information for the journal Drugs is: Adis International LTD, 41 Centorian Dr, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand.
Keywords for this news article include: Drugs, Missouri, Genetics, Leukemia, Oncology, Treatment, Hematology, Pediatrics, Kansas City, Chemotherapy, United States, North and Central America.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC